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A B S T R A C T
Glucocorticoids are one of the most widely used therapeutics in the treatment of a variety of inflammatory
disorders. However, it is known that there are variable patient responses to glucocorticoid treatment; there are
responders and non-responders, or those that need higher dosages. Polymorphisms in the glucocorticoid
receptor (GR) have been implicated in this variability. In this study, ninety-seven volunteers were surveyed for
polymorphisms in the human GR-alpha (hGRα), the accepted biologically active reference isoform. One isoform
identified in our survey, named hGR DL-2, had four single nucleotide polymorphisms (SNPs), one synonymous
and three non-synonymous, and a four base pair deletion resulting in a frame shift and early termination to
produce a 743 amino acid putative protein. hGR DL-2 had a decrease in transactivation potential of more than
90%. Upon further analysis of the individual SNPs and deletion, one SNP, A829G, which results in a lysine to
glutamic acid amino acid change at position 277, was found to increase the transactivation potential of hGR
more than eight times the full-length reference. Furthermore, the hGRα-A829G isoform had a differential
hyperactive response to various exogenous steroids. Increasing our knowledge as to how various SNPs affect
hGR activity may help in understanding the unpredictable patient response to steroid treatment, and is a step
towards personalizing patient care.
1. Introduction
Glucocorticoids are steroid hormones that regulate a variety of
biological processes including stress response, glucose metabolism,
cellular differentiation, and inflammation and immune response [1,2].
They are released from the adrenal cortex in response to trauma,
pathogens, as well as other types of physiological and psychological
stress in an attempt to return the body to homeostasis [3,4]. The
human endogenous glucocorticoid is cortisol. There are a wide range of
diseases that are treated with glucocorticoids: asthma, rheumatoid
arthritis, Graves’ disease, ulcerative colitis, and sepsis [5,6]. Their
potency and diverse effects have made them one of the most widely
prescribed drugs in the world [3]. However, response to glucocorticoid
treatment can also vary greatly between patients; some require more
aggressive treatments at higher doses, some smaller doses, while some
appear to be glucocorticoid resistant [7–12].
Glucocorticoids are reported to act by binding to the glucocorticoid
receptor (GR), a cytoplasm-localized receptor belonging to the nuclear
steroid receptor superfamily [1]. Like the other members of the family,
GRs are known to be comprised of an N-terminal transactivation
domain, DNA binding domain, and a C-terminal ligand binding
domain [5]. The human reference GR (hGR) has nine exons, of which
only exons two through nine are translated into a protein (Fig. 1). Exon
nine is alternatively spliced to form either hGRα or hGRß. hGRα is the
classical GR isoform [13,14]. In the classical GR pathway, upon
binding glucocorticoid, hGRα dissociates from its chaperone proteins
and translocates to the nucleus where it activates or represses various
genes directly by binding to specific transcription regulatory elements
known as the glucocorticoid response element (GRE) and negative GRE
(nGRE), or indirectly by tethering to other transcription factors [13–
16]. hGRß acts as a dominant negative inhibitor of hGRα; however,
hGRß is able to bind the glucocorticoid antagonist RU486, and is also
able to modulate gene transcription independently of hGRα [17,18].
As a key factor in mediating the glucocorticoid response, variations
in the GR have been widely studied. The overwhelming majority of hGR
polymorphisms are connected with loss of function and often gluco-
corticoid resistance [19,20]. There have been relatively few gain-of-
function GR polymorphisms reported and most were generated in the
laboratory [21–23]. However, Tung et al. identified a naturally
occurring hyperactive hGR resulting from a combination of three
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non-synonymous single nucleotide polymorphisms (SNPs): A214G,
T962C, and A2297G [24].
While screening various human subjects for GR polymorphisms, we
identified an isoform, hGR DL-2, that has one synonymous and three
non-synonymous SNPs and a four base pair deletion at position 2201
of the coding sequence. This caused a frame shift and early termination
resulting in a 743 amino acid putative protein (Fig. 1). This isoform
had negligible activity. However, when each individual SNP was
isolated and tested for activity, we found that one SNP, A829G
(K277E) displayed a hyperactive response relative to hGRα.
Identifying alterations such as this may contribute to a greater under-
standing of the variable response to glucocorticoid treatment.
2. Materials and methods
2.1. Study population
The details of the study population have been previously described
[24]. In brief, this study was approved by the institutional review board
of the University of California, Davis, and all participants gave
informed written consent. Excluded from the study were those with
major medical conditions, such as diabetes mellitus, hypertension,
chronic obstructive pulmonary disease, inflammatory bowel disease,
autoimmune diseases, cancer, pregnancy or exogenous steroid regi-
mens. The study cohort consisted of 97 volunteers (70 female and 27
male; 20–67 years of age at the time of blood collection).
2.2. Identification, construction, and nomenclature of hGR isoforms
Total RNA was isolated from the buffy coat using the RNeasy Mini
Prep kit with a modified protocol (Qiagen, Valencia, CA) followed by
reverse transcription with Sensiscript RT (Qiagen). Subsequently, the hGR
coding sequence was amplified by polymerase chain reaction in two
sections: exons 2 to 3 (hGR-1B: tcactgatggactccaaag; hGR 3-2A: aagctt-
catcagagcacacc) and exons 3 to 9α (hGR 3-1A: ccagcatgagaccagatgta;
hGRa-2A: ttaaggcagtcacttttgatgaaac). Each section was cloned into the
pGEM-T Easy vector (Promega, Madison, WI) and sequenced at MC
Laboratories (South San Francisco, CA). Sequences were compared to the
hGRα reference sequence from National Center for Biotechnology
Informatics (NCBI) (NM_001018077) to identify polymorphisms. A
full-length coding sequence was created by combining the fragments after
cutting with restriction enzymes, then sub-cloning into a pcDNA4-HisMax
expression vector (Life Technologies, Grand Island, NY).
Using the hGR DL-2 and hGRα isoforms as templates, each of the
SNPs and the deletion were individually separated into new constructs,
and then each SNP was paired with the deletion in derivative isoforms
using a schema of restriction digests so that the action of each could be
studied independently.
hGR isoforms are named based on structure. hGRα refers to an
isoform that matches the NCBI hGRα reference sequence
(NM_001018077). hGR DL refers to an isoform with a deletion (DL)
followed by a number indicating the sequence in which our laboratory
examined the deletion isoform. Derivative isoforms isolating individual
SNPs are designated by hGRα followed by their SNP change (position
with nucleotide change based on coding sequence). hGR743 has no
SNPs and is named based on the resulting putative protein size.
2.3. Measurement of transactivation potential of hGR isoforms
tsA201 cells (a HEK 293 cell subclone stably transfected with the
SV40 large T-antigen) were a gift from Dr. Daniel Feldman (Shriners
Hospitals for Children Northern California). For each transfection,
tsA201 cells were seeded on a 96-well plate at either 20,000 cells per
well (baseline, no steroid stimulation assay) or 12,000 cells per well
(vehicle and steroid stimulation assay) in 100 µl of antibiotic-free
Dulbecco's Modified Eagle Medium (Life Technologies) supplemented
with 10% fetal bovine serum (JR Scientific, Woodland, CA or Atlanta
Biologicals, Lawrenceville, GA) and incubated at 37 °C with 5% CO2.
The next day the cells were transfected with an hGR isoform and a
glucocorticoid response element (GRE)-luciferase reporter plasmid
(PathDetect GRE Cis-Reporter Plasmid; Agilent Technologies, La
Jolla, CA) using Fugene 6 (Promega) per the manufacturer's protocol.
The following day, for baseline assays, the transactivation potential of
the cells was assessed; otherwise cells were treated with graded doses
of hydrocortisone (1–100 nM), methylprednisolone (10−3 nM to
1 nM), dexamethasone (10−4 nM to 1 nM), or vehicle control. For
hydrocortisone and methylprednisolone 0.9% saline was the vehicle,
and for dexamethasone a solution consisting of 1% benzyl alcohol,
1.1% sodium citrate, and 0.1% sodium sulfite in water was the vehicle.
The concentration ranges were determined based on previous titration
studies to optimize the response of hGR to each steroid (data not
shown). Pharmaceutical-grade hydrocortisone sodium succinate
(Pfizer, New York, NY; clinical anti-inflammatory adult dosage, 15–
240 mg; half-life, 8–12 h), methylprednisolone sodium succinate
(Pfizer; clinical anti-inflammatory adult dosage, 10–40 mg; half-life,
12–36 h), and dexamethasone sodium phosphate (Luitpold
Pharmaceuticals, Shirley, NY; clinical anti-inflammatory adult dosage,
0.4–6 mg; half-life, 36–72 h) were used. A Luciferase Assay Kit
(Agilent Technologies) was used to determine the transactivation
potential of each isoform and luminescence was measured with a
Fig. 1. Coding sequences and protein structure of hGR isoforms. Reference hGR is comprised of nine exons, of which exons two through nine are translated. hGRα, the reference, is
listed first. The start position is indicated with an arrow. hGRα is followed by hGR DL-2 and its derivative isoforms. Based on the coding sequence, SNPs and deletions are indicated on
each isoform. The position of the stop codon for each isoform is marked by a dashed vertical line. Adjacent to each coding sequence is the putative protein. hGRα is translated into a 777
amino acid protein which is made of a transactivation domain, DNA binding domain (D), hinge region (H), and ligand binding domain (LBD). The boundaries of each region are
indicated. The amino acid changes of hGR DL-2 and derivatives are noted for each putative protein. The frame shift caused by the four base pair (bp) deletion results in the last ten
amino acids differing from reference hGRα (black box).
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Perkin-Elmer MicroBeta Trilux (Perkin-Elmer, Waltham, MA).
2.4. Western blot analysis of hGR isoforms
tsA201 cells transfected with recombinant hGR isoforms were
either lysed in ice-cold lysis buffer (Agilent) supplemented with
cOmplete Protease Inhibitor Cocktail (Roche, Indianapolis, IN) and
supernatants harvested and normalized, or were fractionated into
nuclear, cytoplasmic, and membrane extracts using a cell fractionation
kit (Cell Signaling Technology, Danvers, MA). Proteins were run on a
4–20% BioRad Criterion TGX gel (Hercules, CA), then transferred to a
polyvinylidene difluoride membrane (BioRad). Membranes were
blocked with 5% nonfat dry milk, washed, and incubated overnight
with Glucocorticoid Receptor (D8H2) XP (1:1000), MEK1/2 (D1A5)
(1:1000), AIF (D39D2) XP (1:1000), or Histone H3 (D1H2) XP
(1:2000) rabbit monoclonal antibodies (Cell Signaling Technology) in
5% nonfat milk or bovine serum albumin. A secondary anti-rabbit-HRP
(GE Healthcare, Piscataway, NJ) in 5% nonfat milk at 1:2000 was used
for protein visualization via chemiluminescence using the ECL Prime
Western Blot Detection System (GE Healthcare).
2.5. Statistical analysis
All luciferase assays were run in triplicate, except for vehicle
controls which were run in duplicate. Each experiment was repeated
at least three times to confirm the pattern, and then the data from
multiple experiments were combined and normalized for figures and
statistical analysis. The data are presented as means with error bars
representing standard error of the mean. The results were compared
with one-way ANOVA, and the significance was confirmed with a
Tukey's post hoc test.
3. Results
3.1. Identification and transactivation potential of a novel hGR
isoform and its derivatives
The survey of the study population for hGR polymorphisms
identified numerous hGR isoforms with novel SNPs. One isoform
chosen for further analysis because it also contained a deletion was
hGR DL-2. hGR DL-2 had one synonymous (C649T) (rs78063502) and
three novel non-synonymous SNPs (A829G, G1379A, T2153G) result-
ing in respective amino acid changes at positions 277 (transactivation
domain), 460 (DNA binding domain), and 718 (ligand binding
domain). It also had a four base pair deletion at position 2201 of the
coding sequence (Fig. 1), causing a frame shift and early termination
resulting in 743 amino acids versus the 777 amino acids in hGRα, the
reference hGR. The last 10 amino acids of hGR DL-2 also differs from
the reference. Functional analysis of hGR DL-2 found that this isoform
had a more than 90% decrease in activity compared to hGRα (Fig. 2).
To further understand the effect of the variations in hGR DL-2, nine
new constructs were made using hGRα as the base: one for each of the
SNPS (C649T, A829G, G1379A, T2153G) singly, one for each of the
SNPs in conjunction with the four base pair deletion, and one with only
the four base pair deletion (Fig. 1, Supplementary Fig. 1). We found
that the isoform with only the deletion, named hGR743 because of the
resulting truncated protein size, had the same 90% loss in activity as
hGR DL-2 (Fig. 2). The activity of the other SNP isoforms varied.
C649T, the synonymous SNP, and G1379A had no significant effect on
activity compared to hGRα; whereas T2153G, which changed leucine
(L) to arginine (R) at position 718 in the ligand binding domain,
resulted in a significant loss of activity (data not shown). The most
interesting change, however, was the A829G SNP where lysine (K)
became glutamic acid (E) at position 277 in the transactivation domain
and resulted in an isoform that had more than eight times the activity
of hGRα in the absence of steroid stimulation. Despite the significant
increase in activity caused by the presence of A829G, this response was
lost when the SNP was paired with the four base pair deletion. A
Western blot confirmed the protein expression of the hGR isoforms as
well as the resultant decrease in size of the truncated isoforms
(Fig. 3A). Additionally, we looked at the nuclear, cytoplasmic, and
membrane localization of hGRα-A829G in comparison to hGRα by
Western blot (Fig. 3B). Blots for MEK1/2, AIF, and Histone H3
confirmed that protein expression was relatively even in the cytoplas-
mic, membrane, and nuclear fractions, respectively. We found that
hGRα and hGRα-A829G was expressed in all three subcellular com-
partments while the reverse orientation hGRα negative control had no
expression. Furthermore, hGRα-A829G did not have greater nuclear
translocation than hGRα despite having a greater transactivation
potential; in fact, the expression of hGRα-A829G was less than hGRα
in all three fractions.
3.2. hGR isoforms’ differential responses to exogenous steroids
Subsequently, we looked at the response of hGRα-A829G to
exogenous steroids. Initially, the constructs were treated with graded
doses of hydrocortisone (1, 10, or 100 nM). Our previous studies have
Fig. 2. Baseline transactivation potential of hGR isoforms. Without the addition of
exogenous steroids there was a decrease in activity of all truncated isoforms, hGR DL-2,
hGR743, and hGRα-A829G/743 versus hGRα. However, there was a significant increase
in the activity of hGRα-A829G (**, p < 0.01) compared to all other isoforms. Data shown
is a combination of seven experiments and presented as mean ± SEM.
Fig. 3. Expression and subcellular localization of hGR isoforms. (A) A Western blot for
GR confirmed the expression of all isoforms. (B) hGRα, hGRα-A829G, and reverse
orientation hGRα negative control were separated into cytoplasmic, membrane, and
nuclear subcellular fractions and the localization of GR was determined by Western blot.
hGRα had the greatest expression in all three groups. Efficient fractionation of
subcellular compartments was confirmed by the relatively even expression of MEK1/2
for cytoplasm, AIF for membrane, and Histone H3 for nuclear.
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shown that hGRα has a dose dependent response to hydrocortisone
that peaks at ~10 nM [25,26] which was again confirmed in these
studies (Fig. 4A). hGRα-A829G had a matching dose dependent
response to hydrocortisone treatment which also peaked at 10 nM.
However, hGRα-A829G had approximately three times the activity of
hGRα at all concentrations tested. The other constructs containing the
deletion, hGR743 and hGRα-A829G/743, still had no significant
activity despite hydrocortisone stimulation.
hGRα and hGRα-A829G again had similar responses when stimu-
lated with graded doses of exogenous methylprednisolone (10−3, 10−1,
or 1 nM). Both constructs had a dose dependent response that peaked
at 1 nM of methylprednisolone (Fig. 4B). At the two higher concentra-
tions, 10−1 nM and 10−3 nM, the activity of A829G was still signifi-
cantly greater than hGRα, but had only about twice the activity.
Interestingly, at the lowest concentration, 10−3 nM of methylpredniso-
lone had a slight negative effect on hGRα-A829G and decreased the
activity so that there was no difference between hGRα and hGRα-
A829G. Similar to the results seen in hydrocortisone, the hGR743 and
hGRα-A829G/743 deletion isoforms had almost no activity when
treated with methylprednisolone.
Lastly, the response of the hGR isoforms to dexamethasone was
examined. They were treated with 10−4, 10−2, or 1 nM of dexametha-
sone. The results to dexamethasone were very similar to the results to
methylprednisolone (Fig. 4C). Both hGRα and hGRα-A829G had a
dose dependent response that peaked at the highest concentration,
1 nM. And again, the activity of hGRα-A829G was about two times the
activity of hGRα at the two higher concentrations of steroid, 10−2 and
1 nM. However, unlike methylprednisolone, at the lowest concentra-
tion of dexamethasone, there was a difference in activity between
hGRα-A829G and hGRα. The difference was not as great as the other
concentrations, with only about 1.2 times the activity of hGRα. Also, as
seen previously, hGR743 and hGRα-A829G/743 had no significant
activity even when stimulated with exogenous dexamethasone.
3.3. hGR alterations near A829G
The A829G SNPwas found in only one subject in our study population
of 97 volunteers. The small size of our study population precludes any
frequency analysis. Alternatively, as a follow-up, the 1000 Genomes
Project database was surveyed to determine if A829G had been observed
in other individuals and to identify any alterations in the immediate
vicinity of positon 829 as well. We were unable to find A829G in the 1000
Genomes Project database; however, one deletion and 14 SNPs at 11
positions were identified in a 60 base pair region surrounding position
829 (Table 1). Half of the SNPs identified were synonymous. Three of the
SNPs, A799G, A840T, and A846C, were also found in our study
population. The deletion was a six base pair, in-frame deletion at positions
838–843 which removed a lysine and glutamine.Fig. 4. Transactivation potential of hGR isoforms with exogenous steroids. (A) When
stimulated with hydrocortisone, hGRα and hGRα-A829G had a dose dependent response
that peaks at 10 nM of hydrocortisone. The activity of hGRα-A829G with hydrocortisone
was significantly greater than all other isoforms at all concentrations (**, p < 0.01). Even
after hydrocortisone stimulation, hGR743 and hGRα-A829G/743 had almost no activity.
Data shown is a combination of three experiments and presented as mean ± SEM. (B)
When stimulated with methylprednisolone, hGRα and hGRα-A829G had a dose
dependent response that peaked at the highest concentration, 1 nM. The activity of
hGRα-A829G with methylprednisolone is significantly greater than the other isoforms at
10−1 nM and 1 nM (**, p < 0.01); however, at the lowest concentration (10−3 nM) there is
no difference in the activity of hGRα and hGRα-A829G. hGR734 and hGRα-A829G/743
again failed to significantly respond. Data shown is a combination of three experiments
and presented as mean ± SEM. (C) hGRα and hGRα-A829G had a dose dependent
response to dexamethasone stimulation which peaked at 1 nM. At the lowest concentra-
tion of dexamethasone, hGRα-A829G had greater activity than hGRα (*, p < 0.05).
hGRα-A829G also had significantly greater activity than all other constructs at the higher
concentrations of dexamethasone (10−2 and 1 nM) (**, p < 0.01). hGR743 and hGRα-
A829G/743 also had no substantial activity when stimulated with dexamethasone. Data
shown is a combination of three experiments and presented as mean ± SEM. HYD:
hydrocortisone, MPS: methylprednisolone, DEX: dexamethasone.
Table 1
SNPs adjacent to A829G in 1000 genomes database.
A799Ga Serine to Glycine
C801T Synonymous
C804T Synonymous
C804G Synonymous
C804A Synonymous
T807G Serine to Arginine
G811A Valine to Isoleucine
A836G Glutamic acid to Glycine
A840Ta Glutamine to Aspartic acid
A840G Synonymous
T846Ca Synonymous
A850G Isoleucine to Valine
C856T Leucine to Valine
C858A Synonymous
a Also found in the volunteer population for this study.
T.L. Green et al. Biochemistry and Biophysics Reports 9 (2017) 140–145
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4. Discussion
A829G (K277E) was one of many SNPs identified from the
volunteer population. Currently, over 3000 SNPs have been identified
in hGRα overall [27]. An overwhelming majority of the variations
identified have a repressive effect, such as decreased transactivation
potential and glucocorticoid resistance [19,28–30]. For example, a
V423A SNP (T1268C) occurring in the DNA binding domain was found
in a patient with Primary Generalized Glucocorticoid Resistance or
Chrousos syndrome, a disease characterized by generalized, partial,
end-organ insensitivity to glucocorticoids resulting in increased circu-
lating levels of adrenocorticotropic hormone (ACTH) and cortisol
[31,32]. Analysis of the V423A isoform showed that it displayed
decreased DNA binding efficiency, a 72% reduction in transactivation
potential, and delayed nuclear translocation [33]. A second SNP,
G2035A, designated G679S, in the ligand-binding domain, was asso-
ciated with primary glucocorticoid resistance and also had a significant
decrease in transactivation potential accompanied by an approximate
50% decrease ligand binding affinity [34].
Far fewer hyperactive or glucocorticoid sensitive hGR isoforms have
been identified. The most well-known, naturally occurring glucocorti-
coid sensitive variant is N363S (A1220G), which has been linked with a
higher body mass index and increased insulin response to dexametha-
sone [35–37]. More recently, another naturally occurring, glucocorti-
coid sensitive variant caused by an SNP, D401H (G1201C), was
identified [38]. The patient also presented with type 2 diabetes and
visceral obesity, as well as hypertension. Additionally, during a study of
the hGR ligand binding domain, Warriar et al. experimentally gener-
ated two variants, M565R (T1694G) and A573Q (GC1717CA), which
were found to be hyperactive [21]. Our group also identified a
hyperactive hGR isoform, hGR NS-1, from the same study cohort
presented here [24]. The transactivation potential of hGR NS-1 was
more than twice that of the reference hGRα. However, the activity of
hGR NS-1 was a result of a combination of three SNPs (A214G, T962C,
and A2297G) compared to the single SNP of hGRα-A829G, which
results in eight times the activity of hGRα.
Three transactivation domains (τ1, τ2, and AF-2) and three
sumoylation sites (K277, K293, K703) have been identified in hGR
(Fig. 5) [39–42]. The A829G SNP exchanges the basic amino acid
lysine to an acidic glutamic acid at position 277, the first sumoylation
site. This position is directly downstream of the τ1 transactivation
domain, spanning amino acids 77–262 [40,43]. When Hollengerg et al.
removed a group of amino acids from 262 to 404, which contains the
K277, hGR activity was not affected [40]. However, when examining
the effect of sumoylation, a K277R construct was made which
exchanges lysine for a comparable basic arginine. This construct had
a 2.8 fold increase in transactivation compared to reference hGR after
dexamethasone stimulation when assayed with an ARE (androgen
response element)-luciferase reporter; there was no difference in
activity without dexamethasone [39]. Additionally, microarray analysis
showed that altering all three sumoylation sites (K→R) increased the
number of genes regulated by dexamethasone compared to reference
hGR [44]. Therefore, in examining hGRα-A829G, the removal of the
repressive sumoylation site in combination with changing from a
positive amino acid to a negative one (K277E) so close to the critical,
strongly acidic τ1 domain may cause a change in the conformational
shape of hGR in this region, resulting in a significant increase in
transactivation potential by A829G, with and without steroid stimula-
tion. The exact mechanism driving the increase in activity is unknown.
Increased nuclear translocation of hGRα-A829G is not the driving force
behind the increase in transactivation potential, as might be expected
when considering the classical GR pathway. The overall reduced
expression of hGRα-A829G in comparison to hGRα indicates that
there may be an alternative method that is intrinsic to the hGRα-
A829G isoform such as increased DNA binding affinity. Further studies
will be needed to determine the exact mechanism.
Conversely, the deletion of four bases beginning at position 2201 in
hGR743 causes a frame shift and early termination in which the last
ten amino acids (734−743) differ from reference hGRα, resulting in a
significant loss of transactivation potential. The deletion in hGR743
causes an alteration and truncation to the carboxy-terminal AF-2
transactivation domain (727−763) which is part of the essential twelfth
amphipathic α-helix of the ligand binding domain [42,45]. The AF-2 is
conserved among nuclear receptors and interacts with coactivators
[45–47]. hGR743 is similar in size and structure to hGRß, the most
common alternative hGR splice variant. hGRß has 742 amino acids, of
which the last 15 are unique compared to hGRα [48]. In addition to
helix 12 and AF-2, hGRß is also missing helix 11. hGRß is also inactive
and considered to be a dominant-negative inhibitor of hGRα [49]. Yudt
et al. showed that the loss of the twelfth helix accounts for the loss of
transactivation potential in hGRß, but that specific amino acids, K733
and P734, were responsible for the dominant-negative activity [50].
Therefore, although hGR743 retains helix 11, the loss of helix 12 likely
accounts for the loss of activity for which the A829G SNP is unable to
compensate for in the hGRα-A829G/743 isoform [51]. Furthermore,
although the amino acid sequence of hGR743 diverges from hGRα at
position 734, it is likely not to have the dominant-negative activity of
hGRß because hGR743 has a leucine (K) and isoleucine (I) at positions
733 and 734, respectively, and the dominant-negative activity of hGRß
is dependent on specific amino acids K733 and P734 at those positions
[50].
The exact mechanism for the hyperactivity of hGRα-A829G is
unknown. However, the identification of a novel SNP that is drastically
able to alter the transactivation potential of hGRα is significant. The
K277E amino acid change of hGRα-A829G removes a sumoylation site
and lies just outside of the N-terminal τ1 transactivation domain; the
core region in τ1 necessary for transactivation has been localized to
amino acids 187–227 [52]. The change caused by A829G at position
277 supports the role of sumoylation on hGR function and suggests
that τ1 can be significantly influenced by surrounding amino acids.
Furthermore, the overall transactivation domain may need further
refinement to account for interactions with other residues. This will be
particularly significant when considering the number of SNPs near
position 829 identified in the 1000 Genomes Project database. The
function of these alterations is yet unknown; however, the data
presented here shows that single point mutations can significantly
affect hGR function in relation to type and dosage of steroid, and may
clinically influence a patient's glucocorticoid sensitivity or resistance.
As such, identifying a patient's glucocorticoid receptor profile may be
an essential step in tailoring their glucocorticoid therapy to achieve the
maximal therapeutic response while minimalizing the negative effects.
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Fig. 5. Diagram of hGR functional regions. The sumoylation sites and the τ1, τ2, and
AF-2 transactivation domains of the reference hGR are illustrated with their amino acid
positions. S: sumoylation.
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